To all Avila Therapeutics website visitors:
Celgene Corporation closed its acquisition of Avila Therapeutics on March 7th 2012. As a result, Avila Therapeutics is now a wholly-owned subsidiary of Celgene Corporation. The transaction brings to Celgene a highly-selective Bruton’s Tyrosine Kinase (Btk) inhibitor, currently in phase I clinical development, as well as a unique discovery platform for developing targeted covalent drugs that treat diseases through protein silencing.
To access relevant information on the Btk inhibitor program and Avilomics™, please continue to www.celgene.com or use the relevant links below: